Xin Lang Ji Jin·2026-02-26 06:31Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene was established on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - Morgan Stanley's fund holds a significant position in BeiGene, with the Morgan Stanley Health Industry Mixed A Fund (002708) maintaining 231,800 shares, unchanged from the previous period, representing 4.12% of the fund's net value [2] - The Morgan Stanley Health Industry Mixed A Fund has a total size of 1.423 billion CNY and has experienced a loss of 0.47% this year, ranking 8462 out of 8887 in its category, while its one-year return is 0.89%, ranking 7892 out of 8134 [2] Group 3 - The fund manager of the Morgan Stanley Health Industry Mixed A Fund is Wang Dapeng, who has been in the position for 11 years and 39 days, with the fund's total asset size at 1.997 billion CNY. The best return during his tenure is 70.7%, while the worst return is -50.91% [3]